Germany: Crowdsourcing for Psychiatric Diseases New Project Explores Treatment Approaches through Crowdsourcing
Boehringer Ingelheim and Bio Med X have established a new research team that will conduct research to identify novel approaches for the treatment of patients with psychiatric diseases.
Ingelheim/Germany – The members of the team of scientists from around the world had submitted solution approaches in a crowdsourcing competition.
“We are excited about applying the innovative approach of crowdsourcing to harness the creativity of the scientific community and combine it with our internal research and development capabilities, to discover the next generation of medicines for patients with psychiatric diseases who currently have insufficient treatment options,” said Corporate Senior Vice President Clive R. Wood, Head of Discovery Research of Boehringer Ingelheim.
Christian Tidona, founder and Managing Director of Bio Med X explained: “With this new neuroscience research group our center is growing to over 60 top researchers from around the world.”
The interdisciplinary team will focus on the generation of novel therapeutic approaches for psychiatric diseases by developing a highly integrated brain microcircuit model which includes authentic neuronal and non-neuronal cells and supports functional readouts with sufficient robustness and throughput for drug discovery.
Michal Slezak will head the research team that will be established in the Bio Med X Innovation Center located on the campus of the University of Heidelberg, Germany.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 44072809)